CG Oncology, Inc. (CGON)
- Previous Close
32.71 - Open
32.99 - Bid 32.37 x 800
- Ask 32.66 x 800
- Day's Range
31.67 - 34.60 - 52 Week Range
25.77 - 50.23 - Volume
594,544 - Avg. Volume
685,934 - Market Cap (intraday)
2.165B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
68.20
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
cgoncology.comRecent News: CGON
Performance Overview: CGON
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CGON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CGON
Valuation Measures
Market Cap
2.18B
Enterprise Value
1.61B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.04k
Price/Book (mrq)
3.83
Enterprise Value/Revenue
2.99k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
539k
Net Income Avi to Common (ttm)
-72.33M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
566.51M
Total Debt/Equity (mrq)
0.07%
Levered Free Cash Flow (ttm)
--